Highlights Newsletter 3

This newsletter presents you the following key sessions:

1. Podcast with dr. Joshua Sabari about the CHRYSALIS study: Phase I trial of amivantamab in non-small cell
    lung cancer with EGFR exon 20 insertion mutations

2. Trastuzumab deruxtecan induces high rates of tumour control in heavily pretreated, HER2-overexpressing
    advanced non-small cell lung cancer patients

3. Nivolumab prolongs survival and delays disease progression in patients with relapsed malignant
    mesothelioma

4. RNA-customized adjuvant chemotherapy for patients with completely resected stage II-IIIA NSCLC:
    lower toxicity and a numerical survival benefit

5. Platinum-based chemoradiotherapy plus pembrolizumab for unresectable, stage III non-small cell
    lung cancer